Pathophysiologic changes associated with AD begin decades before the appearance of clinical symptoms; it is therefore essential an advancement of the knownledge of the etiopathogenetic process in early stages of disease. Proteomics and metabolomics are powerfull tools for the study and the comprehensive analysis of proteins and low MW compounds in a biological sample. These tools show great potential for the discovery of new biomarkers. Here we analyze recent developments in the application of proteomic and metabolomic technologies for searching new biomarkers for AD.
|Translated title of the contribution||Proteomic and metabolomic approaches in the study of Alzheimer disease (AD)|
|Number of pages||5|
|Publication status||Published - 2014|
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical
- Medical Laboratory Technology